Simultaneous inhibition of the mitogen-activated protein kinase kinase and phosphatidylinositol 3'-kinase pathways enhances sensitivity to paclitaxel in ovarian carcinoma. [electronic resource]
- Cancer science Dec 2007
- 2002-8 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
1349-7006
10.1111/j.1349-7006.2007.00624.x doi
Adenocarcinoma Annexin A5--analysis Antineoplastic Agents, Phytogenic--pharmacology Cell Line, Tumor Dose-Response Relationship, Drug Enzyme Inhibitors--pharmacology Female Humans Mitogen-Activated Protein Kinase Kinases--antagonists & inhibitors Ovarian Neoplasms--drug therapy Paclitaxel--therapeutic use Phosphoinositide-3 Kinase Inhibitors